Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.
Ophthalmology. 2022 Dec;129(12):1344-1356. doi: 10.1016/j.ophtha.2022.07.003. Epub 2022 Jul 12.
To report 5-year treatment outcomes in the Primary Tube Versus Trabeculectomy (PTVT) Study.
Multicenter randomized clinical trial.
A total of 242 eyes of 242 patients with medically uncontrolled glaucoma and no previous incisional ocular surgery, including 125 patients in the tube group and 117 patients in the trabeculectomy group.
Patients were enrolled at 16 clinical centers and randomly assigned to treatment with a tube shunt (350-mm Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC) (0.4 mg/ml for 2 minutes).
The primary outcome measure was the rate of surgical failure, defined as intraocular pressure (IOP) > 21 mmHg or reduced < 20% from baseline, IOP ≤ 5 mmHg, reoperation for glaucoma, or loss of light perception. Secondary outcome measures included IOP, glaucoma medical therapy, and visual acuity.
The cumulative probability of failure after 5 years of follow-up was 42% in the tube group and 35% in the trabeculectomy group (P = 0.21; hazard ratio = 1.31; 95% confidence interval = 0.86-2.01). At 5 years, IOP (mean ± standard deviation) was 13.4 ± 3.5 mmHg in the tube group and 13.0 ± 5.2 mmHg in the trabeculectomy group (P = 0.52), and the number of glaucoma medications (mean ± standard deviation) was 2.2 ± 1.3 in the tube group and 1.3 ± 1.4 in the trabeculectomy group (P < 0.001).
Trabeculectomy with MMC and tube shunt surgery produced similar IOPs after 5 years of follow-up in the PTVT Study, but fewer glaucoma medications were required after trabeculectomy. No significant difference in the rate of surgical failure was observed between the 2 surgical procedures at 5 years.
报告原发性引流管与小梁切除术(PTVT)研究的 5 年治疗结果。
多中心随机临床试验。
共有 242 名患有药物无法控制的青光眼且未接受过任何既往切口性眼手术的患者的 242 只眼,包括管组 125 例和小梁切除术组 117 例。
患者在 16 个临床中心登记,并随机分配接受引流管(350-mm Baerveldt 青光眼植入物)或小梁切除术联合丝裂霉素 C(MMC)(0.4mg/ml 持续 2 分钟)治疗。
主要观察指标是手术失败率,定义为眼压(IOP)>21mmHg 或较基线降低<20%,IOP≤5mmHg,青光眼再手术或光感丧失。次要观察指标包括 IOP、青光眼药物治疗和视力。
5 年随访后,管组的累积失败概率为 42%,小梁切除术组为 35%(P=0.21;风险比=1.31;95%置信区间=0.86-2.01)。5 年时,管组的 IOP(平均值±标准差)为 13.4±3.5mmHg,小梁切除术组为 13.0±5.2mmHg(P=0.52),青光眼药物治疗的数量(平均值±标准差)管组为 2.2±1.3,小梁切除术组为 1.3±1.4(P<0.001)。
在 PTVT 研究中,5 年随访后,MMC 联合小梁切除术和引流管手术的眼压相似,但小梁切除术组需要的青光眼药物治疗更少。两种手术方式在 5 年时的手术失败率无显著差异。